Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript & Summary

November 12, 2024

NASDAQ US Health Care Biotechnology earnings 26 min

Earnings Call Speaker Segments

Melissa Jarel

executive
#1

Thanks, operator, and good morning to all of you. We appreciate you being with us on this Heron Therapeutics conference call today as we go over the company's financial results for the quarter that closed on September 30, 2024. Joining me from Heron are Craig Collard, our Chief Executive Officer; Ira Duarte, Executive Vice President and Chief Financial Officer; Bill Forbes, Executive Vice President and Chief Development Officer; and Kevin Warner, Senior Vice President, Medical Affairs, Strategy and Engagement. If you're on the conference call, slides are available through the webcast, and you can also find them on the Investor Relations page of our website once today's call wraps up. Before we get started, let me briefly remind everyone that the company will be making forward-looking statements during this conference call. Please be aware that anything that isn't a statement of historical fact counts as a forward-looking statement. That covers remarks regarding the company's projections, expectations, plans, beliefs and future performance, and all of these are forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995. Such statements rest on judgment and analysis as of the date of this conference call, and they face numerous important risks and uncertainties that might cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties tied to the forward-looking statements made in this conference call and webcast are described in the Safe Harbor statement in today's press release and in Heron's public periodic filings with the SEC. Except as required by law, Heron assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so. With that said, I'd now like to turn the call over to Craig Collard, Chief Executive Officer of Heron.

Craig Collard

executive
#2

Appreciate that, Melissa. Morning, everybody, and thanks for joining the Heron Therapeutics Q3 2024 earnings call. We're glad to bring you up to speed on what we accomplished during the third quarter, and that covers tightening up our financial guidance, spanning net revenue, adjusted operating expenses, and adjusted EBITDA. On top of that, we've provided a Q4 2024 net revenue guidance range spanning $37 million to $43 million, reflecting the early traction we've already generated in Q4. We also secured FDA approval for the Vial Access Needle, or VAN, on September 24, and we've been written into the final version of the NOPAIN Act, which takes effect in January of 2025. Finally, our collaboration with CrossLink keeps advancing, and we're starting to observe the favorable effect this may deliver for ZYNRELEF going forward. As I walk through my remarks today, I'll go into more depth on each of these Q3 accomplishments. Turning to financial performance: we keep enhancing our financial efficiency even as revenues climb. Across the last 9 months, amid a period of transition and upheaval at the company, revenues rose more than 12%, gross margin went from 41% to slightly above 72%, and gross profit doubled, from $37 million to $75 million. Even more significant, we managed this while burning under $10 million in cash for 2024; with expenses now aligned, every bit of our focus has shifted toward generating revenue growth across our product portfolio. We're already witnessing growth through our weekly sales, which is why we believed it mattered to offer an early glimpse into Q4, a quarter we expect to be outstanding given our net revenue guidance of $37 million to $43 million. Now I'd like to take a few moments to explain why we think the VAN and the NOPAIN Act will prove highly beneficial for ZYNRELEF. Starting with the VAN, which received official approval on September 24. A key challenge with ZYNRELEF has centered on the preparation involved in extracting the drug from the vial while keeping it sterile. As the slide shows, reading left to right, we've cut withdrawal time from a couple of minutes down to under 45 seconds, using a simple, user-friendly device that establishes a sterile setting once the vial is snapped into the VAN; we're in the launch phase now and expect the VAN to reach the market by the first week of December; now on to the NOPAIN Act. CMS put out a proposed rule for the NOPAIN Act covering calendar year 2025 back in June. The act's final version came out just last month, and ZYNRELEF made it into the final rule. The purpose behind this legislation is to make sure patients can get non-opioid options and that doctors aren't given financial reasons to choose opioids instead; given what CMS has done and its backing of non-opioid treatments, we think a lot more commercial insurers may do the same. For Heron, this marks a significant win and should definitely create a helpful tailwind for ZYNRELEF once you factor in the VAN, our broader label, and the larger commercial reach from the CrossLink partnership. Net revenues for total acute care during the quarter came to $7.4 million. ZYNRELEF's net revenues in the quarter reached $6.3 million. APONVIE net revenues for the quarter totaled $1.1 million. Though we're happy with where we are, we recognized that Q3 was still a period of transition. Looking ahead, we think our quarterly growth ought to begin climbing sharply given all the promotional efforts we have in motion; these will affect not just ZYNRELEF but our whole product portfolio. I mentioned earlier the VAN and the NOPAIN Act, and both will make a difference in 2025. At this point, we're already seeing signs that the CrossLink partnership is starting to push ZYNRELEF growth. Close to 700 CrossLink distributors and contractors have been trained by our team, and their initial impact appears here. Whenever a CrossLink rep creates a meaningful effect on an account — such as a key introduction or a trial with a new surgeon — our sales force designated that account as a CrossLink account. On the left side, you can observe a rising count of these CrossLink accounts placing orders for ZYNRELEF. At present, we're adding on average 21 newly ordering CrossLink accounts each month. If we apply a threshold of 20 units during the first month, we're presently averaging 7 of these qualified CrossLink accounts monthly. These figures serve as important inputs to our 2025 forecast. In the center chart, we observe a consistent rise in monthly units across CrossLink accounts overall. And on the right, another perspective on this contribution is the cumulative count of ZYNRELEF units since the CrossLink program launched in April. Almost 40,000 units have been ordered through CrossLink accounts so far, which comes to approximately $4.4 million in net revenue. If you annualize the October units, that would produce more than $10 million in net revenue. I'd like to stress that this program has only just begun and what we're seeing is early. We're quite enthusiastic about what this partnership will deliver once we've been firing on all cylinders for a quarter or two. Turning now to APONVIE. During 2024, we've been bringing our business units together under the One Heron initiative I've talked about before. As a refresher, the One Heron approach was put in place so that every one of our customer-facing teams would sell our full product portfolio, rather than having 2 divisions inside a small company focused only on acute or oncology. Once again, our internal guiding principle is accountability and efficiency. A major advantage we've seen from this strategy is how well the teams have collaborated to secure access to APONVIE and drive its uptake. Our national accounts group, which operates from the top down, along with our specialty access teams, are collaborating closely with the territory business managers in the field to secure wins and ensure coordinated pull-through. Looking at the 2 charts displayed here, APONVIE's growth is unmistakable, and we anticipate heading into 2025 on a fresh trajectory. Over the past 12 months, the count of accounts placing orders for APONVIE has tripled, yet even 182 accounts ordering in October barely begins to tap the potential we see in this product. As an increasing number of providers secure access to APONVIE within their hospitals, the average daily units of APONVIE sold have surged notably in 2024; that's where the new trajectory truly becomes apparent. Taking the 652 average daily units from October and annualizing them would equate to more than $7 million in sales. The momentum we've built with APONVIE has the team highly energized. As with ZYNRELEF, we're eager about what lies ahead. Shifting to how our oncology franchise products have performed. Our oncology franchise remains a solid cornerstone for the company. For the quarter, CINVANTI generated net revenues of $22.6 million, while SUSTOL brought in net revenues of $2.8 million. Even though net revenues dipped somewhat compared to Q2, we expect a robust recovery in Q4 and across 2025. As we've mentioned previously, CINVANTI operates in a highly competitive space, which can lead to quarterly ups and downs, but the clinical benefits of CINVANTI have enabled us to hold roughly a 20% share of that market. We remain confident we'll succeed in the ANDA litigation as well, and we expect CINVANTI to retain full protection through its patent expiry in 2035. At this point, I'll hand things over to Ira Duarte, our CFO, to discuss our financials and provide an update on our financial guidance. Please go ahead, Ira.

Ira Duarte

executive
#3

Thanks, Craig. For the three months that wrapped on September 30, 2024, product gross profit came in at $23.4 million, or 71%, up from 42% in the same stretch of 2023. The main driver was that this quarter didn't carry the large inventory write-offs that hit the comparable quarter of 2023. On a year-to-date basis, product gross profit reached $75.1 million, or 73%, climbing from 41% during the equivalent period in 2023. SG&A expenses for the 3 and 9 months ended September 30, 2024, came to $23.3 million and $77.3 million, respectively, versus $28.8 million and $106.7 million, respectively, in the same period of 2023. That decline stemmed mostly from lower personnel and related costs tied to reductions in force in prior years, along with better cost efficiencies across all departments. Research and development expenses were $4.5 million and $13.5 million for the 3 and 9 months ended September 30, 2024, versus $9.3 million and $31.3 million in the comparable periods of 2023. That decrease came primarily from lower personnel and related costs tied to reductions in force implemented in previous years, plus a decline in development activities. As noted in the 10-Q, the condensed consolidated statements of operations and comprehensive loss as of September 30, 2023, reflects reclassification of certain expenses from research and development to general and administrative expenses to align with the function of the expenses incurred. This resulted in no change to total operating expenses. Net loss was $4.8 million for the 3 months ended September 30, 2024 and $17.2 million for the 9 months ended September 30, 2024, versus $25 million and $99.8 million, respectively, for the comparable periods in 2023. Cash and short-term investments at September 30, 2024, stood at $70.9 million. The overall year-to-date cash burn for the business was less than $10 million. Year-to-date, we incurred inventory write-offs of $2.4 million. Unlike last year's write-offs, current year write-offs were not related to inventory management. In addition, we also recorded asset impairment write-offs of $2.1 million, primarily related to projects no longer part of the company's forward-looking strategy. As you will see on the slide, if you had excluded depreciation, stock-based compensation, inventory write-offs and the asset impairment write-offs, our adjusted EBITDA results would have been a positive $1.4 million operating income which represents a substantial turnaround in the financial management of the business. As a result of our year-to-date cost efficiency measures and overall performance, we are revising our guidance for the rest of the year. We are narrowing our net revenue range from our Q2 guidance of $138 million to $158 million to a revised range of $140 million to $146 million net revenue. We are narrowing our Q2 guidance for adjusted operating expenses which excludes stock compensation, depreciation and fixed asset write-offs from our previous range of $107 million to $111 million to a revised range of $101 million to $105 million. To wrap up, for Q2 our adjusted EBITDA guidance range—which leaves out inventory write-offs, stock compensation, depreciation, and fixed asset write-offs—was negative $10 million to positive $3 million, and we're tightening that to a new range of positive $2 million to positive $5 million. With that, we'd like to begin the question-and-answer portion of the call.

Analyst

analyst
#4

This is Jose <<inaudible>> calling in for Kelly. Now that VAN has gotten the green light, how ought we to be thinking about the adoption trajectory from here on out? And when it comes to the split of customers, what's your expectation between the folks already using ZYNRELEF and those who are new to it?

Craig Collard

executive
#5

Yeah, I appreciate that question. So as things stand, with the VAN, our expectation is that it will be in the market and in customers' hands by the first week of December. What we're planning with that is essentially to begin with a small number of accounts and get people feeling at ease with it, making sure nothing goes wrong as we roll the product out and so on. We're going to locations that already feel very at ease with the product. After that, we'll move on to accounts where we've encountered a problem. By that I mean an account that perhaps has previously walked away because of how the product needed to be prepared. So again, there are quite a few accounts sitting in that bucket. So I believe you've got that. And then clearly, when it comes to any new accounts that CrossLink has brought on, we've been telling them that this device is on its way and will cut down the prep time. So we're really thrilled about what this could do, since it genuinely fixes a problem that's existed for a good while now, related to the prep time of the product, and it also truly tackles <<inaudible>>.

Carl Byrnes

analyst
#6

My questions regarding VAN have gotten their answers. Therefore, I was hoping to return to CINVANTI. Could you perhaps share some thoughts about the subtleties during Q3 when it comes to that sequential drop, and then what you expect for Q4, based on the guidance you gave?

Craig Collard

executive
#7

Sure. Thank you, Carl. Like we mentioned previously, CINVANTI operates in a highly competitive space. There's clearly plenty happening with ASP reimbursement, plus newcomers entering the market, and similar factors. Consequently, our historical share has stayed near 28%. Yet once more, quarterly swings occur in which an account is lost, another is gained, and so on. Thus, during Q3 we did lose one rather sizable account, which clearly appeared in net revenues. However, we intended to — a key reason we issued the guidance for Q4 that we did is that I note, when discussing CINVANTI and in fact the entire product portfolio, that we now follow this kind of One Heron strategy. What I truly mean is that we sell across the whole portfolio. Such a sharp focus had never really existed before with so many of our commercial-facing staff. So what we've genuinely managed to capitalize on, apart from pursuing new accounts, involves the 340B aspect within the hospital for CINVANTI. Therefore, we already observe considerable uptake there in Q4; and thus we anticipate CINVANTI rebounding robustly and, once more, delivering into the following year.

Serge Belanger

analyst
#8

I suppose I'll start with what we saw in the third quarter. Operating expenses also came down a bit compared with the second quarter. I'm just trying to figure out whether that reflects weaker sales during Q3, or whether this is a fresh baseline we ought to assume moving forward? Then, Craig, turning back to the CINVANTI litigation, are you still anticipating a ruling from the court next month, or before the year is out?

Craig Collard

executive
#9

Yeah. No, I appreciate that, Serge. Good to hear from you. Let me — I'd like to restate what you asked. The first item, I believe, concerned OpEx. Well, we keep working to manage OpEx as efficiently as we possibly can. It dropped somewhat lower during Q3. Again, I think that's simply been our management of it. I expect it will more or less flatten out within the range we currently find ourselves in. But — and I'll also let Ira address that. However, I'd like to turn to the litigation briefly and discuss it, and afterward I'll return to Ira. On the litigation, well, our confidence in the case remains extremely strong. Closing arguments took place in August, and we genuinely believe that in the end, we'll prevail once everything is finished, and this must be settled by December 14 of this year. So a decision could truly arrive at any moment; yet once more, we expect to win the case and move forward with the patent running through 2035.

Ira Duarte

executive
#10

Serge, regarding the OpEx figure for Q3 — sure, that happened, though I wouldn't really treat it as some fresh baseline. Essentially, it's a mix of what we saw in Q2 and Q3. A few items simply landed at different times during Q3, and that brought expenses down. So that isn't — that is not the baseline we'll be working from moving ahead.

Serge Belanger

analyst
#11

Alright. Perhaps one final question. When we consider NOPAIN for 2025, what size of a boost might that provide? I believe you currently have fairly thorough coverage in the ASC setting, and HOPDs as well. Just wondering what shifts? And could it truly be — I suppose, what magnitude of a lift could it offer for the ZYNRELEF franchise?

Craig Collard

executive
#12

Do you mean NOPAIN? My apologies, I didn't catch the beginning of that.

Serge Belanger

analyst
#13

Regarding the NOPAIN Act, what size of a boost...

Craig Collard

executive
#14

Yeah. No, listen, I believe, once more, given CrossLink alongside VAN and at this point NOPAIN, I believe this will be an enormous assistance for us. What I mean is, we currently do have reimbursement, yet a problem we've truly endured with for a long stretch is simply being known. And I believe the reality that we appear in the NOPAIN Act, which is getting discussed frequently. These days we're discussing opioid abuse and similar topics. And I believe including us within that discussion, plus the reality that we are the pain relief product with the longest duration available, I believe, will deliver considerable awareness and will generate a considerable boost. Thus we view it as genuinely a major advantage for us moving ahead.

Brandon Folkes

analyst
#15

I'd like to add to what was said about the guidance. When you discuss sequential revenue between 3Q and 4Q, could you go into more detail on the CINVANTI recovery you mentioned, as opposed to how VAN is being taken up for ZYNRELEF? Also — following that thought — what's the right way to consider the VAN tailwind from a timing standpoint? Do you expect that tailwind to start in 4Q? Or ought we to view it as something happening in 2025?

Craig Collard

executive
#16

Yes. Thank you, Brandon. It's good to hear from you. On the subject of — I'll begin with CINVANTI. To repeat, CINVANTI amounted to nothing other than an account loss during Q3. As a result, we managed to secure several additional accounts in Q4. And then what we have — since we started promoting this product throughout the portfolio, which has been underway for several months now. So it wasn't limited to Q4; even so, we gained some business in the hospital and have genuinely observed an uptake and, I'd describe it as, a recovery to the level of quarterly revenues seen before Q3. Consequently, we truly believe that this can carry on into '25 and we might even improve upon where we stood previously. That's the situation with CINVANTI. And then clearly, it comes down to managing ASP, something we've done reasonably well historically. So provided we can hold price and expand within these accounts. Our view is CINVANTI can keep performing going forward; yet I believe the primary lens through which I'd view CINVANTI is as more of a foundational business for us. It gives us, once more, something of a cash cow, so to speak, to finance our efforts on the acute side with ZYNRELEF and APONVIE; so turning to ZYNRELEF, what we observe at present is an uptick, in my view, because of the CrossLink partnership; clearly it isn't because of the Van yet since we don't have it available to market. However, I don't believe the van will make as big a difference in Q4. I mean it will be available and I think there will be some enthusiasm surrounding it. Still, I think a genuine upward trend won't emerge until Q1 '25 and somewhat past that. But that, together with CrossLink, is roughly what we're seeing right now.

Carl Byrnes

analyst
#17

could you provide us with some fresh details regarding how the Prefilled Syringe is progressing?

Craig Collard

executive
#18

appreciate that, Carl. Bill Forbes is seated in this room alongside me, so I will hand things over to him.

William Forbes

executive
#19

Yes, the Prefilled Syringe program keeps moving forward. Earlier, I noted that the hurdles tied to it involved sterilization as well as stability. Along those lines, we achieved quite a bit of solid headway during the last quarter. A minor holdup occurred owing to machine parts that were on back order, though we are working our way past that too. So on the whole, the program is advancing in line with what we anticipated, and our hopes for it run high, since we believe it will deliver an improvement even past whatever the VAN provides. Clearly, Prefilled Syringes will represent the gold standard. Regarding the approval date, our target sits at the very end of 2026, or the first quarter of 2027.

Craig Collard

executive
#20

No, we simply want to express our gratitude to all of you for today's questions and for being with us on this call. And we're eager to talk with everybody again in the next quarter.

Operator

operator
#21

Appreciate it, everyone, for joining us on today's call. That brings the program to a close. You're free to hang up now. Have a good day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Heron Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.